Profile
Sector:
HealthcareCountry:
United StatesIPO:
25 July 2018Website:
http://www.aquestive.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 13 min agoDividend
Analysts recommendations
Institutional Ownership
AQST Latest News
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company focused on developing medicines to improve patients' lives through innovative science and delivery technologies, announced today that a poster presentation on the crossover study for their product candidate, Libervant™ (diazepam) Buccal Film for treating epilepsy in children aged two to five, will be featured at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18. The event will be held in a hybrid format, offering both in-person attendance and live online participation.
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.
Aquestive Therapeutics (NASDAQ: AQST ) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares. Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering.
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.23 per share a year ago.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Aquestive Therapeutics (AQST) closed the most recent trading day at $3.67, moving +0.55% from the previous trading session.
What type of business is Aquestive Therapeutics?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
What sector is Aquestive Therapeutics in?
Aquestive Therapeutics is in the Healthcare sector
What industry is Aquestive Therapeutics in?
Aquestive Therapeutics is in the Drug Manufacturers - Specialty & Generic industry
What country is Aquestive Therapeutics from?
Aquestive Therapeutics is headquartered in United States
When did Aquestive Therapeutics go public?
Aquestive Therapeutics initial public offering (IPO) was on 25 July 2018
What is Aquestive Therapeutics website?
https://www.aquestive.com
Is Aquestive Therapeutics in the S&P 500?
No, Aquestive Therapeutics is not included in the S&P 500 index
Is Aquestive Therapeutics in the NASDAQ 100?
No, Aquestive Therapeutics is not included in the NASDAQ 100 index
Is Aquestive Therapeutics in the Dow Jones?
No, Aquestive Therapeutics is not included in the Dow Jones index
When does Aquestive Therapeutics report earnings?
The next expected earnings date for Aquestive Therapeutics is 07 August 2024